The agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Biocon Biologics said in a statement.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.